AAAAAA

   
Results: 1-25 | 26-43 |
Results: 26-43/43
Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
Authors: Rajkumar, SV Fonseca, R Witzig, TE Gertz, MA Greipp, PR
Citation: Sv. Rajkumar et al., Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma, LEUKEMIA, 13(3), 1999, pp. 469-472
Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma
Authors: Rajkumar, SV Fonseca, R Lacy, MQ Witzig, TE Therneau, TM Kyle, RA Litzow, MR Gertz, MA Greipp, PR
Citation: Sv. Rajkumar et al., Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma, J CL ONCOL, 17(5), 1999, pp. 1551-1557
Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatmentof primary systemic amyloidosis
Authors: Gertz, MA Lacy, MQ Lust, JA Greipp, PR Witzig, TE Kyle, RA
Citation: Ma. Gertz et al., Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatmentof primary systemic amyloidosis, J CL ONCOL, 17(1), 1999, pp. 262-267
Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (clg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group treatment trial E9486
Authors: Trendle, MC Leong, T Kyle, RA Katzmann, JA Oken, MM Kay, NE Van Ness, BG Greipp, PR
Citation: Mc. Trendle et al., Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (clg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group treatment trial E9486, AM J HEMAT, 61(4), 1999, pp. 232-237
Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis
Authors: Gertz, MA Lacy, MQ Lust, JA Greipp, PR Witzig, TE Kyle, RA
Citation: Ma. Gertz et al., Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis, AM J HEMAT, 61(2), 1999, pp. 115-119
Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma
Authors: Rajkumar, SV Fonseca, R Lacy, MQ Witzig, TE Lust, JA Greipp, PR Therneau, TM Kyle, RA Litzow, MR Gertz, MA
Citation: Sv. Rajkumar et al., Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma, BONE MAR TR, 24(5), 1999, pp. 497-503
Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma
Authors: Gertz, MA Lacy, MQ Inwards, DJ Chen, MG Pineda, AA Gastineau, DA Greipp, PR Lust, JA Tefferi, A Witzig, TE Kyle, RA Litzow, MR
Citation: Ma. Gertz et al., Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma, BONE MAR TR, 23(3), 1999, pp. 221-226
Beta(2)-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma
Authors: Rajkumar, SV Fonseca, R Lacy, MQ Witzig, TE Lust, JA Greipp, PR Therneau, TM Kyle, RA Litzow, MR Gertz, MA
Citation: Sv. Rajkumar et al., Beta(2)-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma, BONE MAR TR, 23(12), 1999, pp. 1261-1266
Autologous stem cell transplantation for relapsed and primary refractory myeloma
Authors: Rajkumar, SV Fonseca, R Lacy, MQ Witzig, TE Lust, JA Greipp, PR Therneau, TM Kyle, RA Litzow, MR Gertz, MA
Citation: Sv. Rajkumar et al., Autologous stem cell transplantation for relapsed and primary refractory myeloma, BONE MAR TR, 23(12), 1999, pp. 1267-1272
Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma
Authors: Rajkumar, SV Fonseca, R Dewald, GW Therneau, TM Lacy, MQ Kyle, RA Greipp, PR Gertz, MA
Citation: Sv. Rajkumar et al., Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma, CANC GENET, 113(1), 1999, pp. 73-77
Toward a morphologic classification of multiple myeloma?
Authors: Greipp, PR
Citation: Pr. Greipp, Toward a morphologic classification of multiple myeloma?, LEUK RES, 23(12), 1999, pp. 1141-1142
The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma - Phase III Eastern Cooperative Oncology Group clinical trial EST 9486
Authors: Oken, MM Leong, T Lenhard, RE Greipp, PR Kay, NE Van Ness, B Keimowitz, RM Kyle, RA
Citation: Mm. Oken et al., The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma - Phase III Eastern Cooperative Oncology Group clinical trial EST 9486, CANCER, 86(6), 1999, pp. 957-968
Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders
Authors: Witzig, TE Timm, M Larson, D Therneau, T Greipp, PR
Citation: Te. Witzig et al., Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders, BR J HAEM, 104(1), 1999, pp. 131-137
Long-term survival (10 years or more) in 30 patients with primary amyloidosis
Authors: Kyle, RA Gertz, MA Greipp, PR Witzig, TE Lust, JA Lacy, MQ Therneau, TM
Citation: Ra. Kyle et al., Long-term survival (10 years or more) in 30 patients with primary amyloidosis, BLOOD, 93(3), 1999, pp. 1062-1066
Treatment of the systemic capillary leak syndrome with terbutaline and theophylline - A case series
Authors: Tahirkheli, NK Greipp, PR
Citation: Nk. Tahirkheli et Pr. Greipp, Treatment of the systemic capillary leak syndrome with terbutaline and theophylline - A case series, ANN INT MED, 130(11), 1999, pp. 905-909
Prognosis in multiple myeloma
Authors: Fonseca, R Greipp, PR
Citation: R. Fonseca et Pr. Greipp, Prognosis in multiple myeloma, CANC TREAT, 99, 1999, pp. 155-170
Paclitaxel as the initial treatment of multiple myeloma - An Eastern Cooperative Oncology Group Study (E1A93)
Authors: Miller, HJ Leong, T Khandekar, JD Greipp, PR Gertz, MA Kyle, RA
Citation: Hj. Miller et al., Paclitaxel as the initial treatment of multiple myeloma - An Eastern Cooperative Oncology Group Study (E1A93), AM J CL ONC, 21(6), 1998, pp. 553-556
Chromosomal abnormalities in systemic amyloidosis
Authors: Fonseca, R Ahmann, GJ Jalal, SM Dewald, GW Larson, DR Therneau, TM Gertz, MA Kyle, RA Greipp, PR
Citation: R. Fonseca et al., Chromosomal abnormalities in systemic amyloidosis, BR J HAEM, 103(3), 1998, pp. 704-710
Risultati: 1-25 | 26-43 |